Linked Life Data

6795499

Source:http://linkedlifedata.com/resource/pubmed/id/6795499

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1982-1-9
pubmed:abstractText
Trifluorothymidine (TFT), a thymidine analog, was analyzed for its ability to select for thymidine kinase-deficient (TK-/-) mutants. In comparison with BUdR, the traditional selective agent for TK-/- cells, it was determined that TFT at 1/50th the dose (1 microgram/ml vs. 50 microgram/ml) is a more effective and versatile selective agent for TK-/- mutants arising from the TK+/- -3.7.2C heterozygote of L5178Y mouse lymphoma cells. Since TFT acts more rapidly than BUdR, it can be utilized in procedures (such as the analysis of the phenotypic lag) requiring the fast arrest of cell division. Reconstruction analyses of effective TK-/- mutant recovery indicate that TFT can be used to recover mutants from significantly higher densities of TK+/- cells than can BUdR. In addition, TK-/- mutants can attain larger colony size in TFT than in BudR where severe stunting of growth occurs at high TK-/- cell densities. 190 of 194 isolated TFT-resistant large and small colony mutants (both spontaneous and induced).
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0027-5107
pubmed:author
pubmed:issnType
Print
pubmed:volume
85
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
363-78
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1981
pubmed:articleTitle
The utilization of trifluorothymidine (TFT) to select for thymidine kinase-deficient (TK-/-) mutants from L5178Y/TK+/- mouse lymphoma cells.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S.